IVD Antibody Portfolio

About EXONBIO

ExonBio is a private, early-stage biotech leveraging its patented SPIN® platform to accelerate and enhance monoclonal antibody discovery. The company appears to operate primarily as a service provider and platform developer, offering antibody discovery services and developing diagnostic antibodies for infectious diseases. While currently in a pre-revenue or early-revenue stage, its technology aims to address key bottlenecks in antibody development by isolating antigen-specific plasma cells with high affinity and native chain pairing.

Therapeutic Areas